Novartis Wins Approval for First-of-its-Kind Breast Cancer Treatment 0 28.05.2019 03:00 Feedity.com The approval of Piqray combined with fulvestrant is the first FDA-approved treatment for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
